Miniaturization of a Simulated Gastric Fluid Dispersion Experiment On a Microfluidics System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Miniaturization of a Simulated Gastric Fluid Dispersion Experiment On a Microfluidics System
The miniaturization of preclinical safety assessment studies using a microfluidic chip system and optical microscopy can help reduce compound requirements, time, and costs in formulation development.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 94-100

Acknowledgement

The authors gratefully acknowledge the New Technology Research License Committee of Merck & Co. for funding these experiments as well as Richard Gray, head of sales at Dolomite for helpful discussions.

References

1. P. Li and L. Zhoa, Int. J. Pharmaceutics 341 (1-2), 1-19 (2007).

2. J.B. Dressman and C. Reppas, Eur. J. of Pharm Sci. 11 (S2), S73-S80 (2000).

3. X. Casadevall i Solvas and A. deMello, Chem. Commun. 47 (7), 1936-1942 (2011).

4. Y. Wen and S.T. Yang, Expert Opin. Drug Discov. 3 (10), 1237-1253 (2008).

5. L. Kang et al., Drug Discovery Today 13 (1/2), 1-13 (2008).

6. S. Okushima et al., Langmuir 20 (23), 9905-9908 (2004).

7. V. Ravichandiran, K. Masilamani, and B. Senthilnathan, Der Pharmacia Sinica 2 (1), 19-30 (2011).

8. A. Jahn et al., Langmuir 23 (11), 6289-6293 (2007).

9. S.Y. Teh et al., Lab Chip. 8 (2), 198-220 (2008).

10. P.A. Tabeling, Lab Chip. 9 (17), 2428-2436 (2009).

11. A. Pathak et al., Drug Invention Today 2 (2), 123-129 (2010).

12. W-G. Dai et al., Int. J. Pharmaceutics 336 (1), 1-11 (2007).

13. P. Mansky et al., J. Pharm. Sciv. 96 (6), 1548-1563 (2007).

14. W-G. Dai et al., J. Pharm. Sci. 96 (11), 2957-2969 (2007).

15. S. Gopinathan, A. Nouraldeen, and A.G.E. Wilson, Future Med. Chem. 2 (9), 1391-1398 (2010).

16. C.R. Gardner, C.T. Walsh, and O. Almarsson, Nature Rev. Drug Disc. 3 (11), 926-934 (2004).

17. C.R. Gardner et al., Comp. Chem. Eng. 28 (6-7), 943-953 (2004).

18. H. Gu, M.H.G. Duits, and F. Mugele, Int. J. Mol. Sci. 12 (4), 2572-2597 (2001).

19 X. Casadevall i Solvas et al., Anal. Chem. 82 (9), 3950-3956 (2010).

Nicole L. Hill*, PhD, is a principal scientist in the Basic Pharmaceutical Sciences Group at Merck & Co., 2015 Galloping Hill Road, Kenilworth, NJ 07033, tel: 732.594.2009, nicole_hill@merck.com. Todd Nelson, PhD, is an executive director in the Process Chemistry Group, Tim Rhodes, PhD, is a senior principal scientist in the Analytical Sciences Group, and Allen Templeton, PhD, is an executive director in the Basic Pharmaceutical Science Group, all at Merck & Co. Elizabeth Kwong, PhD, is a consultant with Kwong Eureka Solutions, and formerly a senior scientific director with the Basic Pharmaceutical Sciences Group at Merck & Co. Brian Farrer, PhD, is a principal scientist at Liquidia Technologies, and formerly a principal scientist with the Basic Pharmaceutical Sciences Group at Merck & Co.

*To whom correspondence should be addressed.

Submitted: Oct. 2, 2012; Accepted Nov. 12, 2012.

All figures are courtesy of the authors


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here